Related Experiment Video
Updated: Feb 2, 2026

An Ex vivo Model to Study Hormone Action in the Human Breast
Published on: January 8, 2015
RET rearrangements are actionable alterations in breast cancer
Bhavna S Paratala1,2, Jon H Chung3, Casey B Williams4
1Department of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, 08901, USA.
Abstract:
Fusions involving the oncogenic gene RET have been observed in thyroid and lung cancers. Here we report RET gene alterations, including amplification, missense mutations, known fusions, novel fusions, and rearrangements in breast cancer. Their frequency, oncogenic potential, and actionability in breast cancer are described. Two out of eight RET fusions (NCOA4-RET and a novel RASGEF1A-RET fusion) and RET amplification were functionally characterized and shown to activate RET kinase and drive signaling through MAPK and PI3K pathways. These fusions and RET amplification can induce transformation of non-tumorigenic cells, support xenograft tumor formation, and render sensitivity to RET inhibition. An index case of metastatic breast cancer progressing on HER2-targeted therapy was found to have the NCOA4-RET fusion. Subsequent treatment with the RET inhibitor cabozantinib led to a rapid clinical and radiographic response. RET alterations, identified by genomic profiling, are promising therapeutic targets and are present in a subset of breast cancers.
Insights
RET gene alterations, including fusions and amplification, are found in breast cancer. These alterations can be targeted with RET inhibitors, showing promise for treating certain breast cancer patients.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- The oncogenic RET gene is implicated in thyroid and lung cancers.
- RET gene alterations, such as fusions, are not well-characterized in breast cancer.
Purpose of the Study:
- To investigate the frequency, oncogenic potential, and therapeutic actionability of RET gene alterations in breast cancer.
- To functionally characterize identified RET alterations and their downstream signaling pathways.
Main Methods:
- Genomic profiling to identify RET alterations (amplification, missense mutations, fusions, rearrangements).
- Functional characterization of RET fusions and amplification using cell transformation and xenograft models.
- Assessment of sensitivity to RET inhibition.
Main Results:
- RET alterations, including fusions and amplification, were identified in a subset of breast cancers.
- Characterized RET alterations activated RET kinase, driving MAPK and PI3K signaling.
- These alterations induced cell transformation, supported tumor formation, and were actionable with RET inhibitors.
- A patient with metastatic breast cancer showed a clinical response to a RET inhibitor after progression on HER2-targeted therapy.
Conclusions:
- RET gene alterations represent a novel targetable vulnerability in a subset of breast cancers.
- Genomic profiling can identify patients who may benefit from RET-targeted therapies.
Related Concept Videos
[3,3] Sigmatropic Rearrangement of 1,5-Dienes: Cope Rearrangement
[3,3] Sigmatropic Rearrangement of Allyl Vinyl Ethers: Claisen Rearrangement
Alterations in Respiration II
In Biot's breathing, the respiratory rate and depth are irregular, alternating between periods of deep gasping and apnea. Common causes...
Preparation of Diols and Pinacol Rearrangement
The reaction begins with transferring a proton from the acid catalyst to one of the hydroxyl groups, producing an oxonium ion.
Altered States of Awareness
The ingestion of substances like stimulants or hallucinogens leads to chemical alterations in the brain...
Fixed Action Patterns

